# Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian

> **NCT03412526** · PHASE2 · UNKNOWN · sponsor: **Sheba Medical Center** · enrollment: 15 (estimated)

## Conditions studied

- Metastatic Ovarian Cancer

## Interventions

- **DRUG:** Fludarabine
- **RADIATION:** Radiation
- **BIOLOGICAL:** TIL administration
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT03412526
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-21
- **Primary completion:** 2021-02-01
- **Final completion:** 2022-02-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2019-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03412526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03412526, "Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03412526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*